A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Clinical trial NCT07673744 · RECRUITING
Trial details
- NCT number
- NCT07673744
- Sponsor
- TG Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-30
- Primary completion
- 2028-07-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.